S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.84 (-0.85%)
MSFT   420.46 (-0.23%)
META   488.09 (-1.17%)
GOOGL   151.01 (+0.09%)
AMZN   180.32 (+0.27%)
TSLA   176.77 (-1.70%)
NVDA   904.78 (+0.25%)
NIO   4.53 (-3.00%)
AMD   180.78 (+0.66%)
BABA   72.49 (+1.26%)
T   17.64 (+0.51%)
F   13.21 (+1.15%)
MU   117.96 (-0.99%)
CGC   8.34 (-12.67%)
GE   174.78 (-2.96%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.97 (+0.68%)
PYPL   67.18 (+0.92%)
XOM   116.16 (+1.04%)
NASDAQ:CORT

Corcept Therapeutics (CORT) Stock Price, News & Analysis

$25.29
-0.03 (-0.12%)
(As of 02:33 PM ET)
Today's Range
$25.19
$25.69
50-Day Range
$21.10
$25.32
52-Week Range
$20.87
$34.28
Volume
363,917 shs
Average Volume
1.60 million shs
Market Capitalization
$2.62 billion
P/E Ratio
26.62
Dividend Yield
N/A
Price Target
$33.79

Corcept Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
32.5% Upside
$33.79 Price Target
Short Interest
Bearish
22.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.40mentions of Corcept Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.31 M Sold Last Quarter
Proj. Earnings Growth
41.30%
From $0.92 to $1.30 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.59 out of 5 stars

Medical Sector

93rd out of 939 stocks

Pharmaceutical Preparations Industry

35th out of 433 stocks

CORT stock logo

About Corcept Therapeutics Stock (NASDAQ:CORT)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

CORT Stock Price History

CORT Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
CORT May 2024 32.000 call
CORT Apr 2024 31.000 call
CORT Apr 2024 17.000 put
CORT Aug 2024 32.000 put
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Top 3 Biotech Stocks to Anchor Your Portfolio
Corcept Therapeutics Inc
Plunge into Profits With These 3 Biotech Stocks
A Checkdown Trade on a Small-Cap Biotech Stock
Corcept Therapeutics: Key Catalysts Ahead
Q4 2023 Corcept Therapeutics Inc Earnings Call
Recap: Corcept Therapeutics Q4 Earnings
See More Headlines
Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CORT
CUSIP
21835210
Employees
352
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$33.79
High Stock Price Target
$47.50
Low Stock Price Target
$25.00
Potential Upside/Downside
+32.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$106.14 million
Pretax Margin
25.82%

Debt

Sales & Book Value

Annual Sales
$482.38 million
Cash Flow
$0.98 per share
Book Value
$4.92 per share

Miscellaneous

Free Float
83,021,000
Market Cap
$2.63 billion
Optionable
Optionable
Beta
0.47

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

CORT Stock Analysis - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CORT shares.
View CORT analyst ratings
or view top-rated stocks.

What is Corcept Therapeutics' stock price target for 2024?

6 Wall Street analysts have issued 1 year price objectives for Corcept Therapeutics' stock. Their CORT share price targets range from $25.00 to $47.50. On average, they anticipate the company's stock price to reach $33.79 in the next year. This suggests a possible upside of 32.5% from the stock's current price.
View analysts price targets for CORT
or view top-rated stocks among Wall Street analysts.

How have CORT shares performed in 2024?

Corcept Therapeutics' stock was trading at $32.48 at the start of the year. Since then, CORT stock has decreased by 21.5% and is now trading at $25.49.
View the best growth stocks for 2024 here
.

When is Corcept Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our CORT earnings forecast
.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) released its earnings results on Thursday, February, 15th. The biotechnology company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.03. The biotechnology company had revenue of $135.41 million for the quarter, compared to analysts' expectations of $129.27 million. Corcept Therapeutics had a trailing twelve-month return on equity of 21.98% and a net margin of 21.86%. The firm's quarterly revenue was up 31.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.14 EPS.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $600.0 million-$630.0 million, compared to the consensus revenue estimate of $531.6 million.

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.25%), Vanguard Group Inc. (9.21%), Ingalls & Snyder LLC (8.10%), Parallel Advisors LLC (3.66%), Novo Holdings A S (2.34%) and Dimensional Fund Advisors LP (2.24%). Insiders that own company stock include Daniel N Swisher Jr, Daniel N Swisher, Jr, David L Mahoney, G Leonard Baker, Jr, Gary Charles Robb, Hazel Hunt, Joseph Douglas Lyon, Joseph K Belanoff, Sean Maduck and William Guyer.
View institutional ownership trends
.

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CORT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners